The estimated Net Worth of Jason Drew Smith is at least $708 Tausend dollars as of 31 January 2024. Mr Smith owns over 10,000 units of UroGen Pharma Ltd stock worth over $369,307 and over the last 4 years he sold URGN stock worth over $0. In addition, he makes $338,531 as Gen. Counsel & Chief Compliance Officer at UroGen Pharma Ltd.
Mr has made over 7 trades of the UroGen Pharma Ltd stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of URGN stock worth $138,100 on 31 January 2024.
The largest trade he's ever made was exercising 10,000 units of UroGen Pharma Ltd stock on 31 January 2024 worth over $138,100. On average, Mr trades about 3,788 units every 90 days since 2020. As of 31 January 2024 he still owns at least 26,742 units of UroGen Pharma Ltd stock.
You can see the complete history of Mr Smith stock trades at the bottom of the page.
Jason Drew Smith is the Gen. Counsel & Chief Compliance Officer at UroGen Pharma Ltd.
As the Gen. Counsel & Chief Compliance Officer of UroGen Pharma Ltd, the total compensation of Mr Smith at UroGen Pharma Ltd is $338,531. There are 6 executives at UroGen Pharma Ltd getting paid more, with Elizabeth Barrett having the highest compensation of $25,900,800.
Mr Smith is 49, he's been the Gen. Counsel & Chief Compliance Officer of UroGen Pharma Ltd since . There are 12 older and 2 younger executives at UroGen Pharma Ltd. The oldest executive at UroGen Pharma Ltd is Stuart Holden, 77, who is the Independent Director.
Jason's mailing address filed with the SEC is 400 ALEXANDER PARK DRIVE, , PRINCETON, NJ, 08540.
Over the last 7 years, insiders at UroGen Pharma Ltd have traded over $8,740,363 worth of UroGen Pharma Ltd stock and bought 33,940 units worth $791,524 . The most active insiders traders include Ran Nussbaum, Arie Belldegrun und Kathryn E Falberg. On average, UroGen Pharma Ltd executives and independent directors trade stock every 31 days with the average trade being worth of $214,027. The most recent stock trade was executed by Mark Schoenberg on 10 June 2024, trading 10,000 units of URGN stock currently worth $138,100.
urogen pharma ltd. (nasdaq:urgn) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. the company has developed rtgel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. urogen pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. urogen pharma's lead product candidates, mitogel™ (mitomycin urothelial gel) and vesigel™ (mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. urogen pharma is headquartered in ra’anana, israel with u.s. headquarters in new york.
UroGen Pharma Ltd executives and other stock owners filed with the SEC include: